Technology and Knowledge Transfer

Nathalie is a Commercialisation and Academic Relations Manager, focusing on making Cambridge University’s researchers, academics and students aware of how Cambridge Enterprise can help them. 

Before she joined Cambridge Enterprise Nathalie worked with a specialised engineering company in the secure printing industry, taking a technology to market that had received a substantial Horizon2020 grant. Prior to that she ran a start-up technology platform connecting print to digital, with applications in smart packaging. Before that she worked as a management consultant to the chemicals, healthcare and energy industries.

Nathalie has a PhD in theoretical physics from the University of Amsterdam.

She joined Cambridge Enterprise in November 2022.

Ed is a Business Development Manager and is responsible for increasing revenue generation from technology licenses.

Prior to joining Cambridge Enterprise, Ed worked for a multinational wood pulp company, specialising in biorefinery technology and leading R&D teams in the UK, the Netherlands and Austria, with scale up piloting in both North America and South Africa. The underpinning science for these projects was originally developed in a start-up company that Ed co-founded to commercialise some of his academic research from Imperial College London.

From 2005-2010 Ed was a lecturer in Green Chemistry at Imperial and he holds a PhD in Polymer Chemistry from Durham University. He has co-authored >60 academic papers and patents.

Ed joined Cambridge Enterprise in November 2022.

PA (Job share with Zoe Prior) to Dr Iain Thomas, Interim Head of Technology Transfer and The Technology Transfer Team.

Prior to joining Cambridge Enterprise she spent 2 ½ years working for the Local Authority in Children’s Services, and has a range of administrative experience working in both healthcare and retail sectors.

Anna joined Cambridge Enterprise in July 2022.

Oleksandra is a Senior Commercialisation Associate in the Physical Sciences team.

Prior to joining Cambridge Enterprise Oleksandra worked as a scientist in Corporate Venturing team at Cambridge Display Technology (CDT) Ltd where she was looking for start-up companies to partner with for CDT’s parent company Sumitomo Chemical. She also worked as a chemist in Organic Photodiode team, designing and synthesising new photoactive materials.

Oleksandra holds a PhD in chemistry/photophysics from the University of Sheffield. She also has BSc in Chemistry from Taras Shevchenko National University of Kyiv (Ukraine) and MSc in Applied Chemistry from Kaunas University of Technology (Lithuania).

Oleksandra joined Cambridge Enterprise in August 2022.

Emma is a Senior Commercialisation Associate in the Life Sciences team, providing support for the evaluation of new technologies, protection of intellectual property and developing commercial opportunities arising from University research.

Prior to joining Cambridge Enterprise, Emma spent more than two years as a trainee patent attorney at a top tier UK patent law firm. She previously completed a PhD and short post-doctoral research position in Plant Genetics at the University of Cambridge. She also has a BA in Biological Natural Sciences from the University of Cambridge.

She is an author on five academic publications and is a part-qualified UK and European patent attorney.

Emma joined Cambridge Enterprise in March 2022.

Adam is a Commercialisation Manager in the Physical Sciences Team where he works to commercialise technologies from across the physical sciences.

Prior to joining Cambridge Enterprise, Adam spent approximately fifteen years working in industrial and academic research and innovation settings. He previously worked as Head of Research Programme and CIH Programme Lead for the Centre for Digital Built Britain, funding and managing innovative research as a partner organisation in the £72m Innovate UK-funded Construction Innovation Hub. His work contributed to UKRI’s Transforming Construction Challenge, ensuring industrial impact from academic research, aiming to transform the construction industry via innovative digital tools and ways of working.

Prior to this he was Senior Specialist at Beko, where he was involved in setting up and running parent company Arçelik’s first international R&D centre in Cambridge, developing technologies and new products in collaboration with academic partners and start-ups. He previously worked at Nokia, where he was responsible for developing inventions for Nokia’s next-generation devices. This followed a period of academic post-doctoral research at Cambridge University across a range of topics including novel nanostructures, solar cells, superconductivity, flexible electronic devices and bioimplants, and insect biomechanics.

Adam is trained as a physicist with an MPhys from Lancaster University, a PhD in experimental physics from the University of Bristol, and is a Chartered Physicist.

Adam joined the Cambridge Enterprise team in July 2020.

Zoe shares the role of PA to the Technology Transfer team with Anna Waldock.

Zoe has experience in supporting and leading teams and before joining Cambridge Enterprise was PA to the CEO and Office Manager at software company, IPV. Prior to this, her roles included Team Leader within the HR Department at Anglian Water and People Team Coordinator at Redgate Software.

Zoe holds an ISEB Programme and Project Management qualification.

Zoe joined Cambridge Enterprise in October 2019.

Ione is a Senior Commercialisation Associate in the Life Sciences team providing support for the evaluation of new inventions, protection of IP, developing commercial opportunities and licensing technologies arising from the University.

Prior to joining Cambridge Enterprise, Ione worked as a Grant Scheme Manager at the Royal Society where she managed a portfolio of international grants. She has a PhD from the UCL Institute of Neurology, which has given her experience of working on translational research. She also has a BSc in Biomedical Sciences from the University of Warwick, and an MSc in Neuroscience from UCL.

Ione joined Cambridge Enterprise in July 2019.

Louise is Director of Ceres Agri-Tech, a knowledge-exchange partnership for the agri-tech sector that helps to connect industry to academia, and funds resulting collaborative projects in order to take technology to market.

Previously, Louise chaired the Red Tractor Fresh Produce Scheme and was a member of the Assured Food Standards Board. In addition Louise spent 10 years working at Marks and Spencer plc in a number of technical and commercial roles across their Food Business.

Louise has a PhD in Plant Pathology from the University of Reading and enjoyed post doc positions at the Forestry Commission working on novel biocontrol systems for tree diseases.

Outside of Cambridge Enterprise, Louise chairs the AHDB Soft Fruit Research Advisory Panel and is a member of the AHDB Hort Board. She also chairs the Raspberry Breeding Consortium at James Hutton Ltd, which is a joint research and industry consortium.

Louise joined Cambridge Enterprise in June 2019.

Emma is Commercialisation Manager (AHSS).

Her role is to develop and enhance Cambridge Enterprise’s support for academics, researchers and students in the Arts, Humanities and Social Sciences, with the aim of enabling creative engagements between Cambridge researchers and beneficiaries in business, government and policy, the voluntary and community sector, and wider society.

Prior to joining Cambridge Enterprise, Emma was College Lecturer in Theology at Keble College, Oxford and Lecturer in English at Middlebury College’s Oxford Humanities Programme. She also worked in outreach, public engagement and student recruitment at Cambridge’s Faculty of Divinity.

Emma holds a PhD from the Faculty of English, University of Cambridge. Her monograph, a study of eighteenth-century religious and literary culture, appeared in 2017. She is Executive Secretary of the British Society of Eighteenth-Century Studies.

Emma joined Cambridge Enterprise in December 2018.

Terry is responsible for the commercialisation and diffusion of Life Science and health-related technologies and research arising from the University of Cambridge through the creation of new companies, licensing relationships and partnerships.

In the past year, Terry has been responsible for the commercialisation of several Cambridge technologies, including the licensing of stem cell products and cancer risk prediction tools and the development of investment opportunities in the fields of Flu and Ebola vaccines and a number of opportunities related to cell therapy.

Terry was previously the Head of Intellectual Property and Commercial Research at Guy’s and St Thomas’ Hospital for over 10 years, having founded and grown a technology transfer department that commercialised NHS inventions from ‘bedside to business’. There he commercialised a variety of technologies including medical devices, software, imaging technologies, laboratory products, novel formulations, in vitro diagnostics and service based IP. He has also been involved in the creation of novel partnerships for the National Health Service such as Viapath (a £500m pathology joint venture with Serco) and Essentia Trading Ltd (a facilities spin-out company). In addition, Terry supported the formation of technology-based spin-out companies including Cydar and SpOtOn Clinical Diagnostics amongst others and has served as a Director for several spin-out companies. Terry was also responsible for founding a Proof of Concept investment fund and setting up a commercial research and consultancy service within the NHS to interface with industry. Prior to this, Terry was Acting Director of MediChIP, the NHS Innovation Hub for SE/SW London. He then became part of the change management team responsible for the merger of the London NHS Innovation hubs to form a single tech-transfer unit (NHS Innovations London).

Terry has a PhD in immunology and gene silencing and held a postdoctoral research position within the UK’s first stem cell spin-out company, Cerestem Ltd.

Terry joined Cambridge in February 2018.

Katja assists academics at the University to turn ideas and inventions emerging from the life sciences into commercial opportunities. Together with her colleagues in the Life Sciences team, Katja provides support for the evaluation, protection and licensing of technologies to achieve global impact.

Since joining Cambridge Enterprise, Katja has worked closely with academics in order to support translational research funding applications, protect inventions via patenting and support the marketing and licensing of technologies arising from the University. Katja also helps academics to access Cambridge Enterprise’s network of expertise by connecting them with Entrepreneurs in Residence, consultants and mentors as well as University programmes such as iTeams Cambridge, Experts in Residence at the Cambridge Academy of Therapeutic Sciences, and EnterpriseTECH at Cambridge Judge Business School.

Prior to joining Cambridge Enterprise, Katja worked as a postdoctoral researcher at Queen Mary University of London in the field of microvascular research, investigating the role of endothelial junctional proteins in inflammatory diseases.

Katja studied Biology with a focus on Human and Molecular Biology at the Saarland University in Germany with research projects in the area of prostate cancer and obesity. She holds a PhD in Biochemistry from the Leipzig University in Germany having worked on novel peptide-drug conjugates and therapeutic peptides in the fields of breast cancer and obesity. During her PhD she has worked in collaboration with non-university research institutes such as the Helmholtz Centre for Environmental Research as well as small biotech and pharma companies. She is co-author on six academic publications.

Katja joined Cambridge Enterprise in March 2018.